Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety.
BACKGROUND
The long-term effects of botulinum toxin type A (BoNTA) on the global impairment associated with severe primary axillary hyperhidrosis have not been comprehensively assessed relative to placebo.


OBJECTIVE
To assess the efficacy and safety of 2 dosages of BoNTA compared with placebo in subjects with primary axillary hyperhidrosis.


METHODS
Subjects (N = 322) were randomized to the use of BoNTA (75 U or 50 U/axilla) or placebo in this 52-week, multicenter, double-blind study.


RESULTS
BoNTA treatment significantly reduced daily activity limitations at 4 weeks after injection. A 2-point improvement on the 4-point Hyperhidrosis Disease Severity Scale (HDSS) was reported in 75% of subjects in the 75-U and 50-U BoNTA groups and in 25% of the placebo group (P < .001). Improvements in HDSS scores were corroborated by gravimetric results. The median duration of effect was 197 days, 205 days, and 96 days in the 75-U, 50-U, and placebo groups, respectively. BoNTA was well tolerated.


CONCLUSIONS
The effect of total surface area involvement on treatment efficacy was not evaluated.


CONCLUSIONS
BoNTA treatment effectively reduces the symptoms of primary axillary hyperhidrosis and is well tolerated.
Lowe
Nicholas J
NJ
University of California Los Angeles School of Medicine, USA. cranleyuk@aol.com
Glaser
Dee Anna
DA
Eadie
Nina
N
Daggett
Simon
S
Kowalski
Jonathan W
JW
Lai
Pan-Yu
PY
D000293:Adolescent; D000328:Adult; D000368:Aged; D001365:Axilla; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage* / Q000009:adverse effects; D016001:Confidence Intervals; D018592:Cross-Over Studies; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006945:Hyperhidrosis / Q000175:diagnosis* / Q000188:drug therapy*; D007271:Injections, Intradermal; D008297:Male; D008875:Middle Aged; D011336:Probability; D011788:Quality of Life; D012307:Risk Factors; D012720:Severity of Illness Index; D018709:Statistics, Nonparametric; D016896:Treatment Outcome
D019274:Botulinum Toxins, Type A